Gib Dat Genetic Brand

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.
Doctor doesn't understand confidence Intervals and FDA BE guidelines.

Zpacks are overused, maybe this will make people think twice before asking for one for the sniffles
 
Is it wrong that I want to strangle these idiots?

If I hear another ****** physician state that idiotic percentage range without realizing that the same requirements apply to the brand names from batch to batch. And of course they cite the single outlier. The Teva buproprion. I wonder why they never ask why generics never seem to work better than the brand.

Fricking institutionalized nocebo effect. Will one of you clinical trial dorks do me a favor and make this your pet project.
 
This is all you need to read:

RESULTS:

The mean +/- SD of the GMRs from the 2070 studies was 1.00 +/- 0.06 for C(max) and 1.00 +/- 0.04 for AUC. The average difference in C(max) and AUC between generic and innovator products was 4.35% and 3.56%, respectively. In addition, in nearly 98% of the bioequivalence studies conducted during this period, the generic product AUC differed from that of the innovator product by less than 10%.
CONCLUSIONS:

The criteria used to evaluate generic drug bioequivalence studies support the FDA's objective of approving generic drug formulations that are therapeutically equivalent to their innovator counterparts.
 
Top